And in recent years, for both melanoma and RCC there have been new systemic agents developed that provide clinical benefit, including the anti-CTLA-4 antibody, ipilimumab, and multi-targeted agents such as sunitinib and sorafenib. The gene discussed is CTLA4; the disease is renal cell carcinoma.